RIPK1 and breast carcinoma: Clinical studies also reveal that RIPK1 and MLKL mRNA expression levels exhibit a significant downward trend in breast cancer tissues, potentially increasing intrinsic resistance to lethal signals and enabling evasion of immune surveillance.83